Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
7.34
+0.34 (4.86%)
At close: Apr 22, 2026, 4:00 PM EDT
7.36
+0.02 (0.26%)
After-hours: Apr 22, 2026, 7:54 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
537.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 205.07M |
| Sutro Biopharma | 102.48M |
| ADC Therapeutics | 81.36M |
| Fulcrum Therapeutics | 80.00M |
| Verastem | 30.91M |
| Upstream Bio | 2.85M |
| Lyell Immunopharma | 36.00K |
CADL News
- 2 days ago - Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating - Benzinga
- 20 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - GlobeNewsWire
- 2 months ago - Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus - Benzinga
- 2 months ago - Candel Therapeutics Announces Pricing of Public Offering - GlobeNewsWire